Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus reuteri NCIMB 30242
- Development stage
- Unknown
- Lead developer
- Microbiome Plus
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Lactobacillus reuteri NCIMB 30242** is a probiotic bacterial strain clinically studied for supporting cardiovascular and digestive health. It is granted Generally Recognized As Safe (GRAS) status by the FDA for use as an oral supplement in adults[1]. Its mechanism of action includes cholesterol-lowering via **bile salt hydrolase (BSH)** activity, which deconjugates bile acids, reducing intestinal absorption of cholesterol and promoting its elimination. The strain also modulates the gut microbiome, increases mucin production, and is associated with boosting serum 25-hydroxyvitamin D levels[1][2][5]. Indications supported by clinical studies include maintenance of normal cholesterol, C-reactive protein, and fibrinogen, as well as supporting vitamin D synthesis and overall gut health[1][2][5]. The developer of NCIMB 30242 as a probiotic supplement is Microbiome Plus+.
- Brand names
- Microbiome Plus+ GI ProbioticMicrobiome Plus+ Lactobacillus reuteri NCIMB 30242
- Other names
- L. reuteri NCIMB 30242lactobacillus reuteri NCIMB 30242
02
Targets
BSH (Bile salt hydrolase)
Beyond the preview
Go deeper on lactobacillus reuteri NCIMB 30242.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus reuteri NCIMB 30242.